SESSION TITLE: Lung Cancer II
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM
PURPOSE: The hedgehog signaling pathway (Hh) has been shown to be activated in cancer. GDC-0449 (Vismodegib) is a low-molecular Hh pathway inhibitor that binds to and inhibits Hh pathway receptor SMO. Recently, we could show that GDC-0449 is effective in lung cancer cell lines and that combination with cisplatin gives an additional effect. However, no data of the effect of GDC-0449 on Hh pathway component expressions in lung cancer cell lines is available.